Drug Trial Radar · NCT07219121
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 7, 2025
Primary completion
Mar 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Travere Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
Conditions
- Proteinuria
- Immunoglobulin A (IgA) Nephropathy
- Focal Segmental Glomerulosclerosis
- Kidney Transplant
Interventions
SparsentanDrug
For participants with a kidney transplant with IgAN: Day 1 through Week 2 visit, participants will take 200 mg once daily (QD) prior to the morning meal. At the Week 2 visit, participants will titrate up to 400 mg QD and take this dose through Week 36, if tolerated and determined to be safe by the Investigator. For participants with a kidney transplant with FSGS, or a biopsy finding of both IgAN and glomeruli with FSGS patterns: Day 1 through Week 2 visit, participants will take 400 mg QD prior to the morning meal. At the Week 2 visit, participants will titrate up to 800 mg QD and take this dose through Week 36, if tolerated and determined to be safe by the Investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urinary protein/creatinine ratio (UPCR)Time frame: 36 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Cornell Medical Center
New York, New York
University of North Carolina Chapel Hill
Morrisville, North Carolina
Ohio State University
Columbus, Ohio
Dallas Nephrology Associates
Dallas, Texas
University of Texas
Galveston, Texas
University of Washington
Seattle, Washington
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.